Zeta Global Holdings (ZETA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inv ...

汇丰银行评级上调 - 汇丰银行近期被上调至Zacks Rank 1（强力买入）评级 [1] - 评级上调主要反映盈利预期的上升趋势 这是影响股价最强大的因素之一 [1] - 该评级升级意味着对公司盈利前景的积极评价 可能对其股价产生有利影响 [3] Zacks评级系统 - Zacks评级完全基于公司盈利状况的变化 通过Zacks共识预期跟踪分析师对当前及下一财年的每股收益预测 [1] - 该系统将股票分为五组 Zacks Rank 1股票自1988年以来实现了平均每年+25%的回报率 [7] - 该系统在任何时间点对覆盖的4000多只股票均保持“买入”和“卖出”评级的均衡比例 仅前5%的股票获得“强力买入”评级 [9] 盈利预期修正的影响 - 公司未来盈利潜力的变化 体现为盈利预期的修正 与股价短期走势高度相关 [4] - 机构投资者利用盈利预期计算公司公允价值 盈利预期的调整直接影响其估值模型 进而引发大宗交易导致股价变动 [4] - 盈利预期上升趋势表明公司基本面业务改善 投资者可能因此推高股价 [5] 汇丰银行盈利预期 - 市场预计汇丰银行在2025财年的每股收益为7.27美元 与上年相比没有变化 [8] - 在过去三个月中 汇丰银行的Zacks共识预期已上调4.2% [8] - 评级上调至Zacks Rank 1使汇丰银行位列Zacks覆盖股票中盈利预期修正表现最佳的前5% 暗示其近期股价可能上涨 [10]

Pacasmayo (CPAC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power ...

WSFS Financial (WSFS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a changi ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

It's time for the big three. We've got three stocks, three charts, three trades. Rick Ducat will take us through the charts.And here to take us through his picks today, Tim Bowen, chief technical trainer for stockstotrade. com. Great to see you both.Tim, as always, let's kick things off with a big picture thought on the market this week. >> Yeah. Well, obviously not what we want to see.Uh, you know, the viewers know, you guys know I'm very bullish. AI technology, you know, all of this stuff from a lifelong ...

公司概况 - 公司为专注于肾脏疾病疗法研发和商业化的生物制药公司，总部位于马萨诸塞州剑桥 [1] - 公司在生物制药行业面临其他开发类似疗法公司的竞争 [1] 近期业绩与事件 - 公司计划于2025年11月10日公布季度财报，并将于美国东部时间上午8:00举行电话会议讨论业绩和近期业务亮点 [2] - 华尔街预计公司每股收益为-0.02美元，预计营收约为5820万美元 [2] 估值指标 - 公司市盈率为负值-14.47，市销率约为2.62，即投资者为其每美元销售额支付2.62美元 [3] - 企业价值与销售额比率约为2.20，企业价值与营运现金流比率显著为负，约为-186.85 [3][4] - 收益率为负值，约为-6.91% [4] 财务健康状况 - 公司债务与股东权益比率为1.83，表明债务水平相对较高 [5] - 流动比率约为1.98，表明流动资产几乎是流动负债的两倍，短期财务健康状况尚可 [5]

New York, NY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Pfizer and BridgeBio sell prescription medication to treat transthyretin amyloid cardiomyopathy, a progressive and fatal disease caused by the buildup of a protein called ...

Block (XYZ) shares slumped Friday after the fintech company's quarterly results fell short of Wall Street's expectations on the top and bottom lines. Shares of payments provider Block have lost about one-quarter of their value in 2025. Al Drago / Bloomberg / Getty Images Close Key Takeaways The stock was down about 10% in recent trading, leading decliners in the S&P 500. Read Investopedia's full daily markets coverage here. Block reported adjusted earnings of 54 cents a share on revenue that rose about ...

Intel's stock has surged over 85% in 2025 so far. David Paul Morris / Bloomberg / Getty Images, Matthias Balk / dpa / Getty Images Close Key Takeaways After a string of recent high-profile deals for Intel, could one with Tesla be next? The question became inevitable after Tesla (TSLA) CEO Elon Musk told investors at the electric vehicle maker's shareholder meeting yesterday that the company, which has increasingly shifted its focus on AI and robotics, would need a "gigantic" semiconductor fabrication plant ...